Here is the 8K:
5:28 PM ET 6/14/17 | Dow Jones
HTG Molecular Diagnostics Inc. (HTGM) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on June 14, 2017.
Effective June 14, 2017, HTG Molecular Diagnostics, Inc. (the "Company") entered into a statement of work (the "SOW") with QIAGEN Manchester Limited ("QIAGEN"), a U.K. corporation and wholly owned subsidiary of QIAGEN N.V. The SOW was entered into pursuant to the Company's Master Assay Development, Commercialization and Manufacturing Agreement (the "Master Agreement") with QIAGEN, and addresses development activities expected to be conducted by the Company and QIAGEN in connection with the initial phase of a sponsor project agreement entered into between QIAGEN and a pharmaceutical company ("Initial Phase").
Under the SOW, the Company and QIAGEN are expected to perform development work for the Initial Phase of what is expected to become a multi-stage project leading to the potential development and commercialization of a next generation sequencing-based companion diagnostic assay. The development work is expected to support one of the pharmaceutical company's therapeutic development and commercialization programs. QIAGEN will pay the Company low single digit millions of dollars for the Initial Phase development work performed under the SOW, and the Company and QIAGEN will also share in any net profits (as determined under the Master Agreement) generated by the Initial Phase.
In connection with the execution of the SOW, HTG and QIAGEN also amended the Master Agreement, to provide that, in the event of a change in control, neither party will be able to terminate the SOW, or the Master Agreement to the extent it relates to the SOW.
QIAGEN North American Holdings, Inc., a wholly-owned subsidiary of QIAGEN N.V., owns 833,333 shares of our common stock.
